NCT05806138进行中（未招募）2 期
A Randomized Controlled Trial of the Soluble Guanylate Cyclase Stimulator Vericiguat in Patients With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction (ELEVATE)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 21
- 试验地点
- 2
- 主要终点
- change in CRF (measured by VO2peak)
研究概览
简要总结
The purpose of this study is to find out if adding vericiguat to standard treatment for cancer therapy related cardiac dysfunction (CTRCD) is more effective than standard treatment alone. The addition of vericiguat to the usual treatment could help improve cardiac function, but it could also cause side effects. This study will help researchers find out whether this different treatment is better, the same as, or worse than the usual approach.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Biopsy proven breast cancer (stage I-IV)
- •Cancer treatment related cardiac dysfunction (CTRCD), established by an absolute decrease in LVEF ≥ 10% from baseline/pre-treatment to < 53% and attributable to prior cardiotoxic cancer treatment, per the clinical investigator.
- •Able to complete an acceptable baseline CPET, in the absence of high-risk ECG findings or other inappropriate response to exercise as determined by the PI, as defined by any of the following criteria:
- •Achieving a plateau oxygen consumption, concurrent with an increase in power output;
- •A respiratory exchange ratio ≥ 1.00;
- •Attainment of maximal predicted heart rate, as defined by a peak heart rate within 10bpm of the age predicted maximal heart rate (220 - Age[years]); or if on a beta-blocker, 164 - (age * 0.7)
- •Volitional exhaustion, as measured by a rating of perceived exertion (RPE) ≥ 18 on the BORG scale.
- •Willing to use highly effective contraceptive measures if of child-bearing potential or if the patient's sexual partner is a woman of child-earing potential while receiving study drug and for 30 days after the last dose of study drug:
- •Female subjects should be using highly effective contraceptive measures, and must have a negative pregnancy test (within 6 months prior to study enrollment) and not be breast-feeding prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:
- •Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments
- •Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the postmenopausal range for the institution
- •Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation.
- •Male subjects should be willing to use barrier contraception °Willing and able to comply with the requirements of the protocol.
排除标准
- •Systolic blood pressure < 90 mmHg
- •Concurrent or anticipated use of a long-acting nitrate or NO donor (e.g., nitroglycerin, isosorbide dinitrate, isosorbide 5-mononitrate, pentaerythritol tetranitrate, nicorandil or transdermal NTG patch, or molsidomine).
- •Concurrent or anticipated use of a phosphodiesterase inhibitor (e.g., vardenafil, tadalafil, or sildenafil).
- •Cardiac comorbidity, including any of the following:
- •Hypertrophic cardiomyopathy, restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac sarcoidosis, or amyloid cardiomyopathy
- •Uncontrolled arrhythmia
- •Uncorrected congenital cardiac disease
- •Acute coronary syndrome, percutaneous coronary intervention, or coronary artery bypass graft surgery within 3 months prior to randomization.
- •Symptomatic carotid stenosis, or transient ischemic attack (TIA) or stroke within 3 months prior to randomization.
- •Cardiac transplantation
- •Valvular heart disease requiring surgery or intervention
- •Non-cardiac comorbidity, including any of the following:
- •eGFR < 15ml/min/1.73m^2 (based upon CKD-EPI, Cockroft-Gault, etc.)
- •Severe hepatic insufficiency (e.g., Child-Pugh C)
- •Severe pulmonary disease, such as requiring continuous home oxygen or interstitial lung disease
- •Other medical disorder or condition that in the opinion of the investigator would impair the subject's ability to participate or complete the study
- •Subjects must not have any of the following absolute contraindications to cardiopulmonary exercise testing:
- •Acute myocardial infarction (within 30 days of any planned study procedures)
- •Unstable angina
- •Uncontrolled arrhythmias causing symptoms or hemodynamic compromise,
- •Symptomatic severe aortic stenosis
- •Recurrent syncope
- •Active endocarditis
- •Acute myocarditis or pericarditis
- •Acute pulmonary embolus or pulmonary infarction (within 3 months of any planned study procedures)
- •Thrombosis of lower extremities (within 3 months of any planned study procedures)
- •Suspected dissecting aneurysm
- •Uncontrolled asthma
- •Pulmonary edema
- •Room air desaturation at rest ≤85%
- •Respiratory failure
- •Acute noncardiopulmonary disorder that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis)
- •Mental impairment leading to inability to cooperate.
- •Current alcohol and/or drug abuse
- •Any other condition or intercurrent illness (e.g., symptomatic weight-bearing bone metastases or limited life expectancy < 6-9 months) that, in the opinion of the investigator, makes the participant a poor candidate for the trial
研究组 & 干预措施
Vericiguat plus optimal medical therapy
Experimental
For patients randomized to vericiguat, a starting dose of 2.5mg will be initiated at the randomization visit. At pre-specified titration visits, subjects will be up-titrated to vericiguat 5mg and then to the target dose of vericiguat 10mg using titration criteria based on mean systolic blood pressure and evaluation for clinical symptoms. Vericiguat will be administered in the background of optimal medical therapy for cardiomyopathy/heart failure.
干预措施: Vericiguat (Drug)
Optimal medical therapy
Active Comparator
For patients randomized to the control group, optimal medical therapy for cardiomyopathy/heart failure will be instituted throughout the study period.
干预措施: Optimal medical therapy (Other)
结局指标
主要结局
change in CRF (measured by VO2peak)
时间窗: up to 6 months
For the primary analysis, intervention effect will be evaluated by comparing differences in mean VO2peak changes from baseline to month 6 between the investigational and control groups using the analysis of covariance approach (ANCOVA).
次要结局
- CRF response rate(up to 6 months)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell CarcinomaUrothelial CarcinomaNCT06262516Case Comprehensive Cancer Center94
已完成
3 期
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)Esophageal Squamous Cell Carcinoma (ESCC)Gastroesophageal Junction Carcinoma (GEJC)Esophageal Adenocarcinoma (EAC)NCT04210115Merck Sharp & Dohme LLC703
进行中（未招募）
不适用
A Study of Suizenji in Patients With Unresectable Pancreatic CancerUnresectable Pancreatic CancerNCT05601323SONIRE Therapeutics Inc.90
Unknown
2 期
Dapsone for Acute Ischemia Stroke StudyCerebral StrokeCerebrovascular Accident, AcuteCerebrovascular StrokeStroke, AcuteStrokeNCT01144650Cidat, S.A. de C.V.300
已完成
早期 1 期
Study of Oral Ketamine Versus Placebo for Treating Depression in Patients Undergoing Treatment for CancerCancerDepressionNCT02836288Scott A. Irwin, MD, PhD4